OM:HEMC

Stock Analysis Report

Executive Summary

Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has Hemcheck Sweden's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.9%

HEMC

1.7%

SE Medical Equipment

3.4%

SE Market


1 Year Return

-66.2%

HEMC

32.2%

SE Medical Equipment

9.1%

SE Market

Return vs Industry: HEMC underperformed the Swedish Medical Equipment industry which returned 32.2% over the past year.

Return vs Market: HEMC underperformed the Swedish Market which returned 9.1% over the past year.


Shareholder returns

HEMCIndustryMarket
7 Day-3.9%1.7%3.4%
30 Day4.2%0.6%0.6%
90 Day-28.4%-2.1%2.9%
1 Year-66.2%-66.2%33.6%32.2%13.7%9.1%
3 Yearn/a44.0%26.5%31.2%11.6%
5 Yearn/a69.4%41.4%64.2%29.2%

Price Volatility Vs. Market

How volatile is Hemcheck Sweden's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Hemcheck Sweden undervalued compared to its fair value and its price relative to the market?

1.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate HEMC's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate HEMC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HEMC is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: HEMC is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate HEMC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HEMC is good value based on its PB Ratio (1.2x) compared to the SE Medical Equipment industry average (4.5x).


Next Steps

Future Growth

How is Hemcheck Sweden forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hemcheck Sweden has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Hemcheck Sweden performed over the past 5 years?

-23.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: HEMC is unprofitable, and losses have increased over the past 5 years at a rate of -23.3% per year.

Accelerating Growth: Unable to compare HEMC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HEMC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).


Return on Equity

High ROE: HEMC has a negative Return on Equity (-12.25%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: HEMC is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: HEMC is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Hemcheck Sweden's financial position?


Financial Position Analysis

Short Term Liabilities: HEMC's short term assets (SEK27.5M) exceeds its short term liabilities (SEK3.2M)

Long Term Liabilities: HEMC's short term assets (27.5M) exceeds its long term liabilities (425.5K)


Debt to Equity History and Analysis

Debt Level: HEMC's debt to equity ratio (2.7%) is considered satisfactory

Reducing Debt: HEMC's debt to equity ratio has reduced from 12.8% to 2.7% over the past 5 years.


Balance Sheet

Inventory Level: HEMC has a low level of unsold assets or inventory.

Debt Coverage by Assets: HEMC's debt is covered by short term assets (assets are 21.760700x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HEMC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HEMC has sufficient cash runway for 1.785713 years if free cash flow continues to reduce at historical rates of -27.5% each year.


Next Steps

Dividend

What is Hemcheck Sweden's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate HEMC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HEMC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if HEMC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HEMC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HEMC's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of Hemcheck Sweden's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average board tenure


CEO

Annelie Brolinson 0

0yrs

Tenure

0

Mr. Annelie Brolinson serves as the Chief Executive Officer of Hemcheck Sweden AB (publ). 


Board Age and Tenure

3.8yrs

Average Tenure

46.5yo

Average Age

Experienced Board: HEMC's board of directors are considered experienced (3.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buykr542,00020 May 19
Hjalmar Didrikson
EntityIndividual
Role
Member of the Board of Directors
Director
Shares100,000
Max Pricekr5.42

Ownership Breakdown


Management Team

  • Annelie Brolinson

    Chief Executive Officer

    • Tenure: 0yrs

Board Members

  • Hjalmar Didrikson (45yo)

    Director

    • Tenure: 9.8yrs
  • Torbjörn Koivisto (50yo)

    Director

    • Tenure: 3.8yrs
  • Jenni Björnulfson (48yo)

    Director

    • Tenure: 3.8yrs
  • Anna Dalgaard (40yo)

    Chairman

    • Tenure: 3.8yrs

Company Information

Hemcheck Sweden AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hemcheck Sweden AB (publ)
  • Ticker: HEMC
  • Exchange: OM
  • Founded: 2010
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: kr58.749m
  • Shares outstanding: 15.71m
  • Website: https://www.hemcheck.com

Location

  • Hemcheck Sweden AB (publ)
  • Karlstads universitet
  • Biomedicin
  • Karlstad
  • Värmland County
  • 651 88
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HEMCOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKMar 2017

Biography

Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden. It develops and commercializes a novel product concept HELGE™ that detects hemolysis in blood samples at the point of care. The ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 21:46
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.